Krystexxa is on its way to the EU market
This article was originally published in Scrip
Executive Summary
Savient has had some good news for its lead product, the refractory gout therapy pegloticase (Krystexxa) with the EU's CHMP granting it a positive opinion at its latest meeting on 15-18 October.